Saturday 17 October 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00. In the quarter to June 2026, EPS fell 17.9%, free cash flow fell 3.25% and total debt fell 52.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.09
0.09
+2.25%
Follow EXOZ
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
— | — | 0.00 |
P/S ratio |
— | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (11.28) |
P/FCF ratio |
— | — | 0.00 |
P/Operating CF |
— | — | (99.87) |
P/B ratio |
— | — | 0.00 |
Price to Tangible BV |
— | — | 0.00 |
EV/Sales |
— | — | 0.00 |
EV/EBITDA |
— | — | 0.00 |
EV/Operating CF |
— | — | (15.99) |
EV/FCF |
— | — | (14.77) |
Quick Ratio |
2.27 | 7.84 | 0.39 |
Current Ratio |
2.51 | 8.12 | 0.50 |
Net Debt/EBITDA |
0.31 | 1.70 | 0.04 |
Debt/Assets |
1.08% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.71 | 1.45 | 0.58 |
Capex/Depreciation |
(0.72) | (1.86) | (1.99) |
| (132.56%) | (116.80%) | 0.00% | |
| (96.38%) | (70.65%) | 0.00% | |
ROIC |
(1,438.03%) | (528.52%) | 0.00% |
Return on Tangible Assets |
(291.95%) | (56.52%) | 454.70% |
Average Days of Receivables |
0.00 | 0.00 | 4,594.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 752.50% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 1,909.84% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 401.57% |
Graham Net Nets |
— | — | (0.11) |
Graham Number |
— | — | 0.00 |
Earnings Yield |
— | — | (8.41%) |
Free Cash Flow Yield |
— | — | (7.17%) |
Revenue per Share |
0.00 | 0.00 | 0.01 |
Operating CF per Share |
(0.78) | (1.30) | (0.19) |
Capex per Share |
(0.02) | (0.06) | (0.05) |
Free Cash Flow per Share |
(0.80) | (1.36) | (0.24) |
Cash per Share |
0.36 | 1.48 | 0.01 |
Shareholders Equity per Share |
0.41 | 1.59 | (0.06) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.41 | 1.59 | (0.06) |
Free Cash Flow |
(6.67) | (8.90) | (1.47) |
Working Capital |
2.37 | 9.49 | (1.20) |
Capital Expenditures |
(0.17) | (0.40) | (0.29) |
Net Current Asset Value |
1.37 | 8.21 | (2.73) |
EV/EBIT |
— | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 4.12 |
Price to Operating Income |
— | — | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.31 | 0.24 | 0.19 |
Cash ROIC |
(102.63%) | (44.20%) | 462.43% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
0.63 | 0.81 | — |
Average Payables |
1.08 | 0.81 | — |
Average Assets |
9.50 | 8.30 | — |
Average Common Equity |
6.91 | 5.02 | — |
Columns are period end dates